
|Articles|March 23, 2015
- Immunotherapy (Issue 5)
- Volume 5
- Issue 1
Immunotherapy in GU Cancers
Author(s)Mark A. Rubin, MD
Mark A. Rubin, MD, director, Institute for Precision Medicine, Weill Cornell Medical College, discusses immunotherapy in the field of genitourinary cancers.
Advertisement
Mark A. Rubin, MD, director, Institute for Precision Medicine, Weill Cornell Medical College, discusses immunotherapy in the field of genitourinary cancers.
<<<
Articles in this issue
over 11 years ago
The Rationale for Immunotherapy in NSCLCover 11 years ago
Maximizing Immunotherapy Approaches in Hard-to-Treat Cancersover 11 years ago
Rich Immunotherapy Pipeline for Melanoma Under Wayover 11 years ago
Tumor Antigens and Their Role in Immune Response in Melanomaover 11 years ago
Major Programs Under Way in Immuno-Oncologyover 11 years ago
PD-1 Inhibitors for MelanomaAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer
2
FDA Approves Zanidatamab Combinations for First-Line HER2+ Advanced GEA
3
Are the RASolute 302 Results Overstated for Daraxonrasib in PDAC?
4
First Patient Dosed in Molecular Glue Degrader Trial for mCRPC
5





































